Cardiac imaging with 18F-fluorodeoxyglucose PET/MRI in hypertrophic cardiomyopathy

Journal of Nuclear Cardiology, Oct 2017

Yasuchika Takeishi MD, PhD, Atsuro Masuda MD

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://link.springer.com/content/pdf/10.1007%2Fs12350-016-0686-x.pdf

Cardiac imaging with 18F-fluorodeoxyglucose PET/MRI in hypertrophic cardiomyopathy

Received Sep 18 Cardiac imaging with F-fluorodeoxyglucose PET/MRI in hypertrophic cardiomyopathy Yasuchika Takeishi 0 2 Atsuro Masuda 0 2 Hitoshi Kubo 0 1 Hideyuki Tominaga 0 1 Noboru Oriuchi 0 1 Seiichi Takenoshita 0 PhD 0 1 0 Electronic supplementary material The online version of this article (doi:10.1007/s12350-016-0686-x) contains supplementary material , which is available to authorized users. Reprint requests: Yasuchika Takeishi, MD, PhD , Department of Car- diovascular Medicine, Fukushima Medical University , 1 Hikarigaoka, Fukushima 960-1295 , Japan 1 Advanced Clinical Research Center, Fukushima Medical University , Fukushima , Japan 2 Department of Cardiovascular Medicine, Fukushima Medical University , Fukushima , Japan - Simultaneous imaging with magnetic resonance imaging (MRI) and positron emission tomography (PET) is valuable in various cardiac diseases.1,2 Altered myocardial metabolism has been reported in hypertrophic cardiomyopathy (HCM).3 In this study, we report an instructive case of HCM with intense 18Ffluorodeoxyglucose (FDG) uptake in the hypertrophied myocardium detected by PET/MRI. A 57-year-old female was referred to our hospital for severe left ventricular hypertrophy (LVH). Although she had no symptoms and no history of hypertension, echocardiography demonstrated severe LVH in the mid LV to the apex with no asymmetric septal hypertrophy. Thus, we suspected apical type of HCM and performed FDG-PET/MRI. After fasting for more than 18 hours, the patient was administered unfractionated heparin 50 IU/kg intravenously 15 minutes before FDG administration to suppress physiological FDG uptake on the myocardium.2 Image acquisition was initiated 60 min after FDG administration. Cine MRI images (Videos 1 and 2 in supplementary material) showed severe hypertrophy in the middle region of the LV with no LV outflow obstruction. However, myocardial thinning and reduced wall motion were observed in the apex. Intense FDG uptake was observed in the LV, suggesting a metabolic substrate switching from fatty acids to glucose, and FDG uptake was relatively low, and late gadolinium enhancement was evident in the apex (Figures 1, 2). Fusion images clearly showed FDG uptake on the hypertrophied myocardium. It should be noted that, although we used prolonged fasting and intravenous heparin, distinguishing physiological uptake of FDG from pathological uptake related to metabolic switching might be sometimes challenging. Simultaneous PET/MRI was able to reconstruct accurate fusion images and provided anatomic and metabolic characterizations of the hypertrophied heart. Myocardial biopsy revealed cardiomyocyte hypertrophy with mere disarray, slight fibrosis, and no inflammatory cell infiltration, consistent with pathological findings of HCM. There were no signs suggestive of secondary cardiomyopathy, which represents cardiac hypertrophy. The PET/MRI is a novel useful imaging technology to evaluate structural and functional abnormalities in HCM. FDG was supplied by Nihon Medi-Physics Co., Ltd. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. 1. Rischpler C , Nekolla SG , Kunze KP , Schwaiger M. PET/MRI of the heart . Semin Nucl Med . 2015 ; 45 : 234 - 47 . 2. Wada K , Niitsuma T , Yamaki T , Masuda A , Ito H , Kubo H , Hara T , Takenoshita S , Takeishi Y. Simultaneous cardiac imaging to detect inflammation and scar tissue with 18F-fluorodeoxyglucose PET/ MRI in cardiac sarcoidosis . J Nucl Cardiol . 2016 ; 23 : 1180 - 2 . 3. Tadamura E , Tamaki N , Matsumori A , Magata Y , Yonekura Y , Nohara R , et al. Myocardial metabolic changes in hypertrophic cardiomyopathy . J Nucl Med . 1996 ; 37 : 572 - 7 .


This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.1007%2Fs12350-016-0686-x.pdf

Yasuchika Takeishi MD, PhD, Atsuro Masuda MD. Cardiac imaging with 18F-fluorodeoxyglucose PET/MRI in hypertrophic cardiomyopathy, Journal of Nuclear Cardiology, 2017, 1-2, DOI: 10.1007/s12350-016-0686-x